US Bancorp
GLUE icon

US Bancorp’s Monte Rosa Therapeutics GLUE Stock Holding History

US Bancorp’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$702 Buy
29
+17
+142% +$321 ﹤0.01% 4023
2026
Q1 		$197 Buy
+12
New +$229 ﹤0.01% 4102
2025
Q1 		– Sell
-26
Closed -$180 – 4268
2024
Q4 		$180 Buy
+26
New +$195 ﹤0.01% 4088

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

US Bancorp's GLUE Position: Q2 2026 in Review

US Bancorp increased its Monte Rosa Therapeutics (GLUE) stake by 142% in Q2 2026, buying an estimated $321 and bringing the position to 29 shares worth $702. The position accounts for ﹤0.01% of the portfolio, ranked #4023.

US Bancorp first reported a position in GLUE in Q4 2024 and has held it in 3 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • US Bancorp held 29 shares of Monte Rosa Therapeutics worth $702 as of Q2 2026.
  • US Bancorp bought 17 Monte Rosa Therapeutics shares in Q2 2026, an estimated $321.
  • Monte Rosa Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #4023 holding.
  • US Bancorp first reported a position in Monte Rosa Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.